Inventor · disambiguated record
Nancy Levin
Also filed as: LEVIN NANCY · LEVIN NANCY JANE
6 granted patents·6 pending applications·132 citations·filing 1996–2022
79Inventor score
Files withCELGENE INT II SARL3TAINSKY MICHAEL3CELGENE TRI A HOLDINGS LTD1DAS TAPAN KANTI1GENENTECH INC1
Top patents by PatentIndex Score
12 records- 0189US6620413B1OB protein-polymer chimerasGENENTECH INC·Filed 1996·Granted Sep 16, 2003·121 cites·25 claims
- 0273US9163227B2Anti-diabetic compoundsPFIZER·Filed 2012·Granted Oct 20, 2015·4 cites·14 claims
- 0372US8722622B2FGF21 conjugates and anti-diabetic uses thereofDAS TAPAN KANTI·Filed 2011·Granted May 13, 2014·7 cites·21 claims
- 0469US2023181534A1Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancersCELGENE INT II SARL·Filed 2022·Application pending·0 cites
- 0560US11980606B2Use of marizomib for the treatment of central nervous system (CNS) cancersCELGENE INT II SARL·Filed 2020·Granted May 14, 2024·0 cites·8 claims
- 0653US9797906B2Detectors of serum biomarkers for predicting ovarian cancer recurrenceTAINSKY MICHAEL·Filed 2013·Granted Oct 24, 2017·0 cites·5 claims
- 0752US2006205660A1OB protein-immunoglobulin chimerasSAUVAGE FREDERIC D·Filed 2006·Application pending·0 cites
- 0851US2018106810A1Detectors of serum biomarkers for predicting ovarian cancer recurrenceTAINSKY MICHAEL·Filed 2017·Application pending·0 cites
- 0949US2020085789A1Use of a proteasome inhibitor for the treatment of central nervous system (cns) cancersCELGENE INT II SARL·Filed 2018·Application pending·0 cites
- 1048US10782302B2Detectors of serum biomarkers for predicting ovarian cancer recurrenceTAINSKY MICHAEL·Filed 2017·Granted Sep 22, 2020·0 cites·2 claims
- 1138US2017348284A1Use of marizomib for the treatment of central nervous system (cns) cancersCELGENE TRI A HOLDINGS LTD·Filed 2017·Application pending·0 cites
- 1237US2015121248A1System for effectively communicating conceptsLEVIN JONATHAN·Filed 2014·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →